Harpreet Singh, PhD , CEO / Immatics Biotechnologies GmbH Info

Jocelyn Arel / Goodwin Procter LLP Info

Jocelyn Arel is a pioneer in the U.S. for her innovative work for clients on SPACs, with nearly two decades of successful SPACs transactions under her belt. Ms. Arel advises clients in all aspects of the SPAC lifecycle, including the formation and… [show more]

Jocelyn Arel is a pioneer in the U.S. for her innovative work for clients on SPACs, with nearly two decades of successful SPACs transactions under her belt. Ms. Arel advises clients in all aspects of the SPAC lifecycle, including the formation and structuring sponsor entities, representing SPACs and SPAC sponsors in initial public offerings (“IPOs”); representing operating companies, their investors and SPACs in business combinations, or “SIPO transactions”; structuring the debt and equity financing transactions that are often needed to facilitate the closing of SIPO transactions; and, advising investors in both SPAC IPOs and SIPO transactions. In addition to her extensive knowledge of the legal issues related to SPACs, Ms. Arel has a deep understanding of the business, financial and marketing issues that affect the success of SPACs. In addition to her leadership in the SPAC market, Ms. Arel represents clients in a wide range of capital market transactions, including initial and follow-on public offerings, private placements of debt and equity, alternative financing and 144A transactions, mergers and acquisitions and joint ventures. She has extensive experience in cross-border financings and acquisitions, as well as in providing advice on other U.S.-based activities for companies headquartered in Canada. A significant portion of Ms. Arel’s practice includes counseling clients on ongoing reporting requirements of public companies, corporate governance matters and various other matters affecting public companies, their officers and directors. She also has considerable expertise in structuring and executing secondary sales and other private liquidity programs for private companies and their investors. [hide]

Gil Bar-Nahum , Managing Director / Jefferies LLC Info

Dr. Gil Bar-Nahum is a Managing Director in the Global Healthcare Investment Banking Group and leads the International Biotechnology effort at Jefferies. Dr. Bar-Nahum has over 17 years of experience and was an Executive Director in UBS Investment… [show more]

Dr. Gil Bar-Nahum is a Managing Director in the Global Healthcare Investment Banking Group and leads the International Biotechnology effort at Jefferies. Dr. Bar-Nahum has over 17 years of experience and was an Executive Director in UBS Investment Bank's Global Healthcare Group until 2009. Prior to that, Dr. Bar-Nahum worked as a Biotechnology Research Analyst for UBS where he served as an Associate Director covering companies in the Life Sciences space. Dr. Bar-Nahum has executed and advised on over 100 transactions in the life sciences space, with particular expertise in Biotechnology Mergers and Acquisitions, and in raising capital for highly innovative developmental stage growth companies. In the last several years, Dr. Bar-Nahum has led follow-on financings and Initial Public offerings of numerous international Biotechnology Companies, including 10 foreign private issuers onto NASDAQ, raising north of $2bn in proceeds. Dr. Bar-Nahum received his PhD in biochemistry from the Sackler Institute at the New York University School of Medicine. The subject of Dr. Bar-Nahum's doctorate work was published twice in the journal Cell. Dr. Bar- Nahum also received an MS from New York University [hide]

Chad Rubin , Managing Director / Solebury Trout Info

Chad has more than 18 years of experience in advising life science companies on topics including shareholder targeting, investor roadshows, capital markets transactions, messaging, and scenario analysis. His experience includes work in finance… [show more]

Chad has more than 18 years of experience in advising life science companies on topics including shareholder targeting, investor roadshows, capital markets transactions, messaging, and scenario analysis. His experience includes work in finance, consulting and market analysis, helping clients move from creation to follow-on and convertible offerings to M&A/IPO. Chad is involved in capital transactions with corporate clients and has counseled clients on domestic and cross-border transactions, and binary data events. Recent engagement and representation highlights include: * Advised a Phase 2 oncology company on release of clinical data, including KOL support/events, positioning and roadshows with the Wall Street community highlighting the data * Managed multiple private offerings for private life sciences and ag biotech companies from series A through series C * Managed 50M euro private placement for Genfit, a Euronext listed company with a Phase 3 trial ongoing in NASH * Assisted multiple companies through the pre-IPO process including strategy and support around messaging, materials, investor and analyst roadshows, syndicate selection and organizational support Prior to joining Solebury Trout in 2005, Chad was the head of the Biotechnology Capital Markets Intelligence Group at Thomson Financial, assisting life sciences companies in their understanding of Wall Street as it pertains to financing transactions, sales and trading dynamics, and perception around clinical and regulatory events. Chad holds a B.A. in Business Administration with a concentration in Finance from Franklin & Marshall College as well as a minor in Film and Media studies. Chad is a member of the Board of Trustees for the Histiocytosis Association and founder of “All Jacked Up,” an annual event that has raised more than $1M for research and awareness of histiocytic disorders. Chad holds Series 7, 79 and 63 securities licenses. When not at work, Chad enjoys fishing, gardening, running, cycling, coaching lacrosse and football, playing guitar and hanging out with his family of five. [hide]